A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors

被引：0

作者：

Xue, J. ^{[1
]}

Sun, Y. ^{[2
]}

Li, D. ^{[3
]}

Guo, Y. ^{[1
]}

机构：

[1] Shanghai East Hosp, Tongji Univ, Sch Med, Med Oncol, Shanghai, Peoples R China

[2] Shandong First Med Univ, Phase I Clin Study Dept, Canc Hosp, Jinan, Peoples R China

[3] Shandong First Med Univ, Med Oncol, Canc Hosp, Jinan, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2175

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1036P

引用

页码：S629 / S629

页数：1

共 50 条

[21] Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China. [J].

Xu, Jian-Ming ;

Qin, Shukui ;

Zhang, Yun ;

Zhang, Yaoyue ;

Jia, Ru ;

Liu, Rongrui ;

Zhang, Gairong ;

Zhao, Chuanhua ;

Lu, Ni ;

Liu, Huilong ;

Xu, Wenlian ;

Fu, Meng ;

Cao, Walt ;

Lu, Haolan ;

Liu, David ;

Dong, Ruiping ;

Wang, Xiaoxiao ;

Wang, Pilin ;

Xu, Ting ;

Gong, John .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[22] Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors [J].

Day, D. ;

Ganju, V. ;

Chung, K. ;

Si, L. ;

Mao, L. ;

Aghmesheh, M. ;

Hoyer, R. ;

Brewin, K. ;

Zeng, S. ;

Lu, Q. ;

Jiang, C. ;

Ren, F. ;

Wu, X. ;

Guo, J. .

ANNALS OF ONCOLOGY, 2023, 34 :S625-S625

[23] A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors [J].

Katsuya, Yuki ;

Ikeda, Masafumi ;

Koyama, Takafumi ;

Sato, Jun ;

Okada, Mao ;

Matsubara, Nobuaki ;

Kondoh, Chihiro ;

Mukohara, Toru ;

Watanabe, Kazuo ;

Kotani, Daisuke ;

Ogawa, Yoshimi ;

Taoka, Shose ;

Yamamoto, Noboru .

CANCER SCIENCE, 2025, 116 (04) :1012-1022

[24] VSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors [J].

Powell, S. F. ;

Patel, M. R. ;

Merchan, J. ;

Strauss, J. ;

Cripe, T. P. ;

Old, M. O. ;

Diaz, R. M. ;

Reckner, M. ;

Brunton, B. ;

Packiriswamy, N. ;

Upreti, D. ;

Suksanpaisan, L. ;

Vandergaast, R. ;

Khan, R. ;

Russell, S. J. ;

Peng, K. W. ;

Bexon, A. S. .

ANNALS OF ONCOLOGY, 2018, 29

[25] First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors [J].

Daud, Adil ;

Albany, Costantine ;

Velcheti, Vamsidhar ;

Hauke, Ralph J. ;

Ahnert, Jordi Rodon ;

Karp, Daniel D. ;

Tsimberidou, Apostolia Maria ;

Cohen, Julia Wanda ;

Schmidt, Emmett V. ;

Wang, Jieyi ;

Chan, C. Hubert ;

Fu, Siqing .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[26] A phase I trial of ATG-101, an investigational PD-L1 x 4-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN [J].

Xue, J. ;

Wen, J. ;

Xiong, J. ;

Sun, Y. ;

Zhao, J. ;

Guo, Y. .

ANNALS OF ONCOLOGY, 2024, 35 :S711-S711

[27] A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer [J].

Daphne Day ;

John J. Park ;

Jermaine Coward ;

Ben Markman ;

Charlotte Lemech ;

James C. Kuo ;

Amy Prawira ;

Michael P. Brown ;

Sarwan Bishnoi ;

Dusan Kotasek ;

R. Matthew Strother ;

Rasha Cosman ;

Rila Su ;

Yiding Ma ;

Zenglian Yue ;

Hui-han Hu ;

Rachel Wu ;

Peiqi Li ;

Archie N. Tse .

British Journal of Cancer, 2023, 129 :1608-1618

[28] A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer [J].

Day, Daphne ;

Park, John J. ;

Coward, Jermaine ;

Markman, Ben ;

Lemech, Charlotte ;

Kuo, James C. ;

Prawira, Amy ;

Brown, Michael P. ;

Bishnoi, Sarwan ;

Kotasek, Dusan ;

Strother, R. Matthew ;

Cosman, Rasha ;

Su, Rila ;

Ma, Yiding ;

Yue, Zenglian ;

Hu, Hui-han ;

Wu, Rachel ;

Li, Peiqi ;

Tse, Archie N. .

BRITISH JOURNAL OF CANCER, 2023, 129 (10) :1608-1618

[29] First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors [J].

Elena Elez, Maria ;

Tabernero, Josep ;

Geary, David ;

Macarulla, Teresa ;

Kang, S. Peter ;

Kahatt, Carmen ;

Soto-Matos Pita, Arturo ;

Fernandez Teruel, Carlos ;

Siguero, Mariano ;

Cullell-Young, Martin ;

Szyldergemajn, Sergio ;

Ratain, Mark J. .

CLINICAL CANCER RESEARCH, 2014, 20 (08) :2205-2214

[30] Phase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA [J].

Papadopoulos, K. P. ;

Harb, W. ;

Lu, N. ;

Ma, X. ;

He, Y. ;

Yuan, L. ;

Fu, M. ;

Lin, Y. ;

Xu, W. ;

Wang, X. ;

Wang, P. ;

Xu, T. ;

Dong, R. ;

Gong, J. .

ANNALS OF ONCOLOGY, 2018, 29 :405-405

← 1 2 3 4 5 →